Oral Wegovy OK'd

Weight-loss drugs in this class usually start with a tiny needle, not a glass of water. The new twist is that the same active ingredient in Wegovy now has a tablet version the Food and Drug Administration approved in the United States. (fda.gov) The drug is semaglutide, which copies a gut hormone called glucagon-like peptide-1. That hormone tells the brain and stomach that food has arrived, so people feel full sooner and stay full longer. (nejm.org) Getting that hormone effect into a pill has been unusually hard because stomach acid and digestive enzymes break peptide drugs apart like scissors cutting thread. Novo Nordisk’s tablet uses an absorption helper so some semaglutide can cross the stomach lining before it gets destroyed. (nejm.org) The approval rests on a late-stage study called OASIS 4, which tested a 25 milligram oral dose once a day in adults with overweight or obesity. The trial randomly assigned 307 people to semaglutide or placebo for 64 weeks alongside diet and physical-activity counseling. (nejm.org) By week 64, people taking the pill lost an average of 13.6% of their body weight, versus 2.2% in the placebo group. About 79% of the semaglutide group lost at least 5% of body weight, compared with 31% on placebo. (nejm.org) The side effects looked like the rest of the glucagon-like peptide-1 family: nausea, vomiting, diarrhea, constipation, and abdominal pain. In OASIS 4, gastrointestinal side effects were mostly mild to moderate and happened most often while the dose was being increased. (nejm.org) The Food and Drug Administration label shows the tablet is taken once daily and the dose is stepped up over time to reduce stomach side effects. The same label carries the boxed warning already used on semaglutide products about thyroid C-cell tumors seen in rodents. (fda.gov) This does not replace the weekly shot for everyone. The injection still gives patients a once-a-week option, while the tablet trades the needle for a stricter daily routine and specific administration instructions. (fda.gov) Novo Nordisk has been building this into a broader semaglutide lineup that already includes Ozempic for type 2 diabetes, Rybelsus as an oral diabetes tablet, and injectable Wegovy for obesity. The new approval turns Wegovy itself into a two-format brand: shot and pill. (novonordisk-us.com, fda.gov) That matters because a daily pill can reach people who never start an injectable drug, even when the drug works. Novo Nordisk was already signaling that strategy in February 2026 with a consumer campaign built around putting a Wegovy pill “in consumers’ hands,” and the Food and Drug Administration approval now makes that plan real. (novonordisk-us.com)